Compare ARLO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | ANAB |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2018 | 2017 |
| Metric | ARLO | ANAB |
|---|---|---|
| Price | $13.25 | $47.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $24.00 | ★ $60.18 |
| AVG Volume (30 Days) | ★ 995.6K | 482.0K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $509,572,000.00 | $169,467,000.00 |
| Revenue This Year | $4.76 | $135.51 |
| Revenue Next Year | $7.31 | N/A |
| P/E Ratio | $379.51 | ★ N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $7.84 | $12.21 |
| 52 Week High | $19.94 | $52.47 |
| Indicator | ARLO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 55.71 |
| Support Level | $13.00 | $44.25 |
| Resistance Level | $14.26 | $48.53 |
| Average True Range (ATR) | 0.49 | 3.02 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 19.84 | 70.35 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).